Is It Too Late to Buy Eli Lilly? Billionaire Ken Griffin Doesn't Think So. He Nearly Quadrupled His Stake in the Pharma Stock in Q2.

Eli Lilly’s Q2 revenue was about $23.0B (+48% YoY), driven by strong volume growth in Mounjaro ($9.9B) and Zepbound ($4.9B), reinforcing metabolic-health momentum. The article highlights late-stage pipeline expansion in obesity (e.g., retatrutide, orforglipron) and Alzheimer’s (Kisunla donanemab with full US FDA approval and EU marketing authorization), supporting a multi-year growth narrative. It also notes Ken Griffin nearly quadrupled Citadel’s stake by ~740,000 shares and that analysts’ price targets cluster around ~$1,366 (high ~$1,600), but flags the stock’s ~ $700 to ~$1,240 run as making valuation a key consideration.

Analysis

The right way to think about LLY is not as a simple growth story, but as a crowded expectation trade. The franchise is still the cleanest way to own metabolic medicine, yet the stock now embeds a long runway of uninterrupted share gains and no meaningful competitive missteps; that leaves very little margin for error if payer pushback, supply normalization, or better oral competition shows up over the next 3-6 quarters. The second-order loser is not just NVO, but any smaller GLP-1 adjacent platform that needs capital markets to fund catch-up trials, because LLY’s scale can force a pricing reset across the category.

Kisunla is more option value than a near-term earnings lever. Alzheimer’s is operationally messy: diagnosis, infusion logistics, safety monitoring, and specialty-channel bottlenecks all slow uptake, so the market may be overestimating how quickly this becomes a material P&L contributor. If adoption disappoints, the thesis does not break, but one of the bull case pillars weakens and the multiple becomes harder to defend.

For the next 1-3 months, the key catalyst is not press-release enthusiasm but whether prescription momentum can stay ahead of an already-high bar without gross margin leakage. Over 6-18 months, the real risk is category normalization: once weight-loss drugs become less scarce and more payer-managed, the market will pay less for volume growth and more for durable net pricing, where competitors can narrow the gap. The contrarian view is that the move may be overdone on quality, not on fundamentals; the business can keep compounding while the stock underperforms simply because the bar is now too high.

Key Decisions for Investors

• Do not chase LLY outright after strength; wait for a 8-12% pullback or the next quarter's script/gross-margin read to confirm the growth rate is still beating expectations before adding.
• For existing LLY longs, finance the position with covered calls 3-6 months out to monetize elevated valuation and reduce downside if the multiple compresses on any payer or competition scare.
• Relative-value idea: long NVO / short LLY in a small size as a 3-6 month valuation convergence trade; thesis is that both can grow, but LLY has less room for any disappointment. Stop if LLY raises guidance materially or NVO loses share faster than expected.
• Set an alert on Kisunla uptake and reimbursement data over the next 1-2 quarters; if specialty-center penetration remains thin, remove Alzheimer’s from the bull case and treat it as immaterial option value.
• If you need obesity exposure with less multiple risk, prefer a basket or pair trade rather than a single-name LLY overweight until oral incretin data and payer coverage become clearer.